Nano Targeting & Therapy (NTT) Biopharma Inc. is an innovative biotech company developing silica nanocarrier platforms designed to successfully optimize drug delivery substances through patented mesoporous silica nanoparticle (MSN) technology. Our aim is to develop nanomedicine therapies for diseases with complex drug delivery issues like brain cancer, immunotherapies, and ocular diseases.
MESOPOROUS SILICA NANOPARTICLE AS A DRUG-DELIVERY PLATFORM FOR OVERCOMING THE HURDLES OF DRUG DELIVERY
Mesoporous silica nanoparticle (MSN) offers the prospect of wide therapeutic applications with the goal of developing drugs with better efficacy and improved safety and toxicological profiles by leveraging their greater chemical/biological activity and surface reactivity. NTT Biopharma’s unique MSN technology has overcome drug delivery problems faced in oncology, CNS, and ocular disease.